Limits...
Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH

Related in: MedlinePlus

Patient disposition
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4372674&req=5

keu338-F1: Patient disposition

Mentions: Fifty-one consenting patients were enrolled and chose to either discontinue (n = 34) or continue (n = 17) abatacept. Nine of the 34 patients from the discontinuation group restarted abatacept at the investigator’s discretion (n = 8) or due to relapse (n = 1). Six patients from the discontinuation group (with an additional patient withdrawn after resumption) and two from the continuation group dropped out of the study, leaving a total of 28 and 15 patients, respectively. Nineteen patients from the discontinuation group remained biologic-free at week 52 (Fig. 1). The demographic and baseline characteristics of the 51 patients enrolled are summarized in Table 1. The two groups had comparable baseline characteristics, except for significantly shorter disease duration and significantly less joint damage in terms of JSN and TSS in those who discontinued abatacept at enrolment (P < 0.05 for all comparisons).Fig. 1


Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.

Takeuchi T, Matsubara T, Ohta S, Mukai M, Amano K, Tohma S, Tanaka Y, Yamanaka H, Miyasaka N - Rheumatology (Oxford) (2014)

Patient disposition
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4372674&req=5

keu338-F1: Patient disposition
Mentions: Fifty-one consenting patients were enrolled and chose to either discontinue (n = 34) or continue (n = 17) abatacept. Nine of the 34 patients from the discontinuation group restarted abatacept at the investigator’s discretion (n = 8) or due to relapse (n = 1). Six patients from the discontinuation group (with an additional patient withdrawn after resumption) and two from the continuation group dropped out of the study, leaving a total of 28 and 15 patients, respectively. Nineteen patients from the discontinuation group remained biologic-free at week 52 (Fig. 1). The demographic and baseline characteristics of the 51 patients enrolled are summarized in Table 1. The two groups had comparable baseline characteristics, except for significantly shorter disease duration and significantly less joint damage in terms of JSN and TSS in those who discontinued abatacept at enrolment (P < 0.05 for all comparisons).Fig. 1

Bottom Line: Clinical, functional and structural outcomes were compared between those who continued and those who discontinued abatacept.Those attaining DAS28-CRP < 2.3 or < 2.7 without abatacept at the endpoint had significantly lower HAQ-DI score and/or CRP at enrolment.Non-serious adverse events occurred in three patients who continued or resumed abatacept.

View Article: PubMed Central - PubMed

Affiliation: Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Department of Rheumatology, Matsubara Mayflower Hospital, Kato, Department of Rheumatology, Taga General Hospital, Hitachi, Division of Rheumatology and Clinical Immunology, Department of Medicine, Sapporo City General Hospital, Sapporo, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Hospital, Kitakyushu, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo and Tokyo Medical and Dental University, Tokyo, Japan. tsutake@z5.keio.jp.

Show MeSH
Related in: MedlinePlus